Tumor rejection antigen precursor
AssigneeLudwig Institute of Cancer Research
InventorsYao-Tseng Chen, Elisabeth Stockert, Yachi Chen, Pilar Garin-Chesa, Wolfgang J. Rettig, Lloyd J. Old
Life of this patent
Estimating the term…
Abstract
The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.
Claims9
An isolated MAGE-1 tumor rejection antigen precursor which is either (i) a glycoprotein having a molecular weight of about 46 kilodaltons as determined by SDS-PAGE, or is (ii) a recombinantly produced protein having a molecular weight of about 34.3 kilodaltons as determined by SDS-PAGE, wherein said MAGE-1 tumor rejection antigen precursor comprises an epitope to which monoclonal antibody MA454, produced by hybridoma cell line ATCC 11540 binds.
Isolated protein consisting of amino acids 57-219 coded for by nucleotides 3931-4761 of the nucleotide sequence of SEQ I.D. NO.:1.
Isolated peptide selected from the group consisting of:
- SEQ ID NO:2
- SEQ ID NO:3, and
- SEQ ID NO:4.
Dependencies are inferred from the claim text.